Literature DB >> 30529013

Identification of a Robust Methylation Classifier for Cutaneous Melanoma Diagnosis.

Kathleen Conway1, Sharon N Edmiston2, Joel S Parker3, Pei Fen Kuan4, Yi-Hsuan Tsai2, Pamela A Groben5, Daniel C Zedek5, Glynis A Scott6, Eloise A Parrish2, Honglin Hao7, Michelle V Pearlstein7, Jill S Frank2, Craig C Carson7, Matthew D Wilkerson8, Xiaobei Zhao2, Nathaniel A Slater7, Stergios J Moschos9, David W Ollila10, Nancy E Thomas11.   

Abstract

Early diagnosis improves melanoma survival, yet the histopathological diagnosis of cutaneous primary melanoma can be challenging, even for expert dermatopathologists. Analysis of epigenetic alterations, such as DNA methylation, that occur in melanoma can aid in its early diagnosis. Using a genome-wide methylation screening, we assessed CpG methylation in a diverse set of 89 primary invasive melanomas, 73 nevi, and 41 melanocytic proliferations of uncertain malignant potential, classified based on interobserver review by dermatopathologists. Melanomas and nevi were split into training and validation sets. Predictive modeling in the training set using ElasticNet identified a 40-CpG classifier distinguishing 60 melanomas from 48 nevi. High diagnostic accuracy (area under the receiver operator characteristic curve = 0.996, sensitivity = 96.6%, and specificity = 100.0%) was independently confirmed in the validation set (29 melanomas, 25 nevi) and other published sample sets. The 40-CpG melanoma classifier included homeobox transcription factors and genes with roles in stem cell pluripotency or the nervous system. Application of the 40-CpG melanoma classifier to the diagnostically uncertain samples assigned melanoma or nevus status, potentially offering a diagnostic tool to assist dermatopathologists. In summary, the robust, accurate 40-CpG melanoma classifier offers a promising assay for improving primary melanoma diagnosis.
Copyright © 2018 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30529013      PMCID: PMC6535139          DOI: 10.1016/j.jid.2018.11.024

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  81 in total

1.  Terminology and management of dysplastic nevi: responses from 145 dermatologists.

Authors:  Maxwell A Fung
Journal:  Arch Dermatol       Date:  2003-10

Review 2.  Gene silencing in cancer in association with promoter hypermethylation.

Authors:  James G Herman; Stephen B Baylin
Journal:  N Engl J Med       Date:  2003-11-20       Impact factor: 91.245

3.  Combined restriction landmark genomic scanning and virtual genome scans identify a novel human homeobox gene, ALX3, that is hypermethylated in neuroblastoma.

Authors:  Katharina Wimmer; Xiao-xiang Zhu Xx; Jean Marie Rouillard; Peter F Ambros; Barbara J Lamb; Rork Kuick; Markus Eckart; Andreas Weinhäusl; Christa Fonatsch; Sam M Hanash
Journal:  Genes Chromosomes Cancer       Date:  2002-03       Impact factor: 5.006

4.  Mutations and copy number increase of HRAS in Spitz nevi with distinctive histopathological features.

Authors:  B C Bastian; P E LeBoit; D Pinkel
Journal:  Am J Pathol       Date:  2000-09       Impact factor: 4.307

5.  Promoter methylation profiling of 30 genes in human malignant melanoma.

Authors:  Junichi Furuta; Yoshihiro Umebayashi; Kazuaki Miyamoto; Kanako Kikuchi; Fujio Otsuka; Takashi Sugimura; Toshikazu Ushijima
Journal:  Cancer Sci       Date:  2004-12       Impact factor: 6.716

6.  Inter-observer variation in the histopathological diagnosis of clinically suspicious pigmented skin lesions.

Authors:  Lieve Brochez; Evelien Verhaeghe; Edouard Grosshans; Eckhart Haneke; Gérald Piérard; Dirk Ruiter; Jean-Marie Naeyaert
Journal:  J Pathol       Date:  2002-04       Impact factor: 7.996

7.  Tandem BRAF mutations in primary invasive melanomas.

Authors:  Nancy E Thomas; Audrey Alexander; Sharon N Edmiston; Eloise Parrish; Robert C Millikan; Marianne Berwick; Pamela Groben; David W Ollila; Dianne Mattingly; Kathleen Conway
Journal:  J Invest Dermatol       Date:  2004-05       Impact factor: 8.551

8.  Classifying melanocytic tumors based on DNA copy number changes.

Authors:  Boris C Bastian; Adam B Olshen; Philip E LeBoit; Daniel Pinkel
Journal:  Am J Pathol       Date:  2003-11       Impact factor: 4.307

Review 9.  Cancer epigenomics.

Authors:  Christoph Plass
Journal:  Hum Mol Genet       Date:  2002-10-01       Impact factor: 6.150

10.  Profiling epigenetic inactivation of tumor suppressor genes in tumors and plasma from cutaneous melanoma patients.

Authors:  Dave S B Hoon; Mia Spugnardi; Christine Kuo; Sharon K Huang; Donald L Morton; Bret Taback
Journal:  Oncogene       Date:  2004-05-13       Impact factor: 9.867

View more
  10 in total

1.  Characterization of the CpG Island Hypermethylated Phenotype Subclass in Primary Melanomas.

Authors:  Kathleen Conway; Yihsuan S Tsai; Sharon N Edmiston; Joel S Parker; Eloise A Parrish; Honglin Hao; Pei Fen Kuan; Glynis A Scott; Jill S Frank; Paul Googe; David W Ollila; Nancy E Thomas
Journal:  J Invest Dermatol       Date:  2021-11-27       Impact factor: 7.590

Review 2.  Through the looking glass and what you find there: making sense of comparative genomic hybridization and fluorescence in situ hybridization for melanoma diagnosis.

Authors:  Jayson Miedema; Aleodor A Andea
Journal:  Mod Pathol       Date:  2020-02-17       Impact factor: 7.842

3.  Genes regulated by DNA methylation are involved in distinct phenotypes during melanoma progression and are prognostic factors for patients.

Authors:  Debora D'Angelo Papaiz; Flávia Eichemberger Rius; Ana Luísa Pedroso Ayub; Clarice S Origassa; Hemant Gujar; Diogo de Oliveira Pessoa; Eduardo Moraes Reis; Jérémie Nsengimana; Julia Newton-Bishop; Christopher E Mason; Daniel J Weisenberger; Gangning Liang; Miriam Galvonas Jasiulionis
Journal:  Mol Oncol       Date:  2022-02-04       Impact factor: 7.449

4.  Epigenomic and genomic analysis of transcriptome modulation in skin cutaneous melanoma.

Authors:  Wuzhen Chen; Pu Cheng; Jingxin Jiang; Yunqing Ren; Dang Wu; Dan Xue
Journal:  Aging (Albany NY)       Date:  2020-07-07       Impact factor: 5.682

Review 5.  Clinical Implications of Primary Cilia in Skin Cancer.

Authors:  Abrar Choudhury; Neil M Neumann; David R Raleigh; Ursula E Lang
Journal:  Dermatol Ther (Heidelb)       Date:  2020-01-29

Review 6.  Molecular Biomarkers for Melanoma Screening, Diagnosis and Prognosis: Current State and Future Prospects.

Authors:  Dekker C Deacon; Eric A Smith; Robert L Judson-Torres
Journal:  Front Med (Lausanne)       Date:  2021-04-16

7.  ENPP2 Methylation in Health and Cancer.

Authors:  Maria Panagopoulou; Dionysios Fanidis; Vassilis Aidinis; Ekaterini Chatzaki
Journal:  Int J Mol Sci       Date:  2021-11-04       Impact factor: 5.923

8.  Pre-diagnostic DNA methylation in blood leucocytes in cutaneous melanoma; a nested case-control study within the Norwegian Women and Cancer cohort.

Authors:  Christian M Page; Therese H Nøst; Vera Djordjilović; Magne Thoresen; Arnoldo Frigessi; Torkjel M Sandanger; Marit B Veierød
Journal:  Sci Rep       Date:  2022-08-20       Impact factor: 4.996

9.  Identification of differentially expressed methylated genes in melanoma versus nevi using bioinformatics methods.

Authors:  Congcong He; Yujing Zhang; Hanghang Jiang; Xueli Niu; Ruiqun Qi; Xinghua Gao
Journal:  PeerJ       Date:  2020-06-03       Impact factor: 2.984

10.  Promoter hypermethylation of CD133/PROM1 is an independent poor prognosis factor for head and neck squamous cell carcinoma.

Authors:  Zele Hu; Huigao Liu; Xinrong Zhang; Bin Hong; Zhenhua Wu; Qun Li; Chongchang Zhou
Journal:  Medicine (Baltimore)       Date:  2020-03       Impact factor: 1.817

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.